Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. corolla

CORolla

"CORolla® - a disruptive ""spring like"" metallic device for permanent treatment of diastolic heart failure."

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 CORolla project word cloud

Explore the words cloud of the CORolla project. It provides you a very rough idea of what is the project "CORolla" about.

more    ejection    aligns    4    threatening    life    19    manages    function    financial    world    aging    time    animals    grant    treat    25    corolla    individuals    people    health    harnesses    trials    topcat    company    ago    fraction    releases    effect    ec    form    million    spring    left    implanted    2    cardiovascular    sme    market    diastole    65    start    augmentation    preserved    complete    validation    augment    energy    families    device    heart    total    internal    paragon    though    humans    drugs    solution    representing    first    introduces    globally    occurs    impaired    accounting    trajectory    expanding    national    interatrial    treatment    needing    instrumental    congestive    shunting    patients    minimally    perfectly    elastic    hfpef    frame    inside    filling    relaxation    women    2021    dynamics    older    clinical    diastolic    corassist    procedure    reg    vision    social    economic    trial    prevalence    population    annually    self    sales    systole    invasive    metallic    planning    instrument    contraction    ventricular    hf   

Project "CORolla" data sheet

The following table provides information about the project.

Coordinator		 CORASSIST CARDIOVASCULAR LTD 

Organization address
address: 114TH MORIYA AVE
city: HAIFA
postcode: 3461805
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Israel [IL]
 Project website https://www.corassist.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CORASSIST CARDIOVASCULAR LTD IL (HAIFA) coordinator 50˙000.00

Map

 Project objective

Heart Failure with preserved ejection fraction (HFpEF) is a life-threatening form of congestive heart failure condition annually affecting more than 25 million people globally. HFpEF occurs commonly in older individuals and has higher prevalence in women. As the European population is aging (over 65 accounting for 19.2% of the total European population, 2.4% more than 10 years ago), HFpEF will affect more and more people, representing significant economic and social challenge for the patients, their families and National Health Systems.

Currently there is no solution on the market for such heart failure condition. Though the effect of some drugs used in the treatment of HF with reduced ejection fraction are currently studied for HFpEF in large clinical trials (e.g. PARAGON-HF Trial, TOPCAT Study), a new approach based on the left interatrial shunting is needed.

The CorAssist introduces a “spring-like” metallic device, CORolla® for augmentation of diastolic function of the heart. The CORolla® is implanted inside the left ventricular of the heart in a minimally invasive procedure. The self-expanding, internal device harnesses the elastic energy during systole (contraction) state and releases it during diastole (relaxation) in order to augment dynamics of left ventricular relaxation and filling. CORolla® manages to impact directly and improve the impaired diastolic function, needing only one-time procedure.

CorAssist Cardiovascular has the vision to become the first company in the world to treat HFpEF. The EC grant is instrumental to this ambitious goal and company’s growth trajectory. Following a very promising validation in animals and humans, the company is planning to start first sales of CORolla® by the end of 2021.The SME Instrument project perfectly aligns with this objective, as it would provide the company with the financial resources necessary to complete the clinical study within the planned time-frame.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COROLLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COROLLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More